US Critical Metals Corp
USCM
Mydecine Innovations Group Inc
MYCO
Three Valley Copper Corp
TVC.H
Tuga Innovations Inc
TUGA
Windfall Geotek Inc
WIN
CA Stock MarketDetailed Quotes
CTX Crescita Therapeutics Inc
- 0.550
- 0.0000.00%
15min DelayMarket Closed Dec 2 16:00 ET
10.51MMarket Cap-3928P/E (TTM)
0.000High0.000Low0Volume0.000Open0.550Pre Close0.00Turnover0.69052wk High0.00%Turnover Ratio19.12MShares0.36052wk Low-0.14EPS TTM9.24MFloat Cap2.000Historical HighLossP/E (Static)16.80MShs Float0.350Historical Low-0.1EPS LYR0.00%Amplitude--Dividend TTM0.65P/B1Lot Size--Div YieldTTM
Crescita Therapeutics Inc Key Stats
Quarterly+Annual
YOY
| (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 18.50%3.59M | -20.81%4.09M | 8.56%5M | -25.52%17.52M | -21.64%4.73M | -49.72%3.03M | -20.73%5.16M | -7.05%4.6M | 40.29%23.53M | -20.26%6.03M |
| Operating revenue | 18.50%3.59M | -20.81%4.09M | 8.56%5M | -25.52%17.52M | -21.64%4.73M | -49.72%3.03M | -20.73%5.16M | -7.05%4.6M | 40.29%23.53M | -20.26%6.03M |
| Cost of revenue | 6.06%1.63M | -11.47%1.85M | 38.53%2.59M | -30.79%7.16M | -22.38%1.67M | -50.42%1.53M | -26.95%2.09M | -16.66%1.87M | 53.12%10.34M | -26.31%2.15M |
| Gross profit | 31.22%1.97M | -27.17%2.24M | -11.88%2.41M | -21.38%10.36M | -21.24%3.06M | -48.98%1.5M | -15.85%3.07M | 0.88%2.74M | 31.64%13.18M | -16.47%3.89M |
| Operating expense | 8.99%3.14M | -0.49%3.28M | 5.72%3.14M | -2.63%12.32M | -4.23%3.17M | 2.67%2.88M | -4.41%3.3M | -3.76%2.97M | 17.89%12.65M | -6.31%3.31M |
| Selling and administrative expenses | 13.14%2.67M | 2.55%2.81M | 6.73%2.35M | -4.33%10.12M | -7.20%2.58M | 3.24%2.36M | -5.97%2.74M | -6.75%2.2M | 21.25%10.57M | -8.02%2.78M |
| -General and administrative expense | ---- | ---- | 6.73%2.35M | ---- | ---- | ---- | ---- | -6.75%2.2M | ---- | ---- |
| Research and development costs | 9.79%157K | -8.43%163K | 6.25%170K | 14.78%699K | 36.25%218K | -11.18%143K | 10.56%178K | 25.98%160K | -3.94%609K | -6.43%160K |
| Depreciation amortization depletion | -17.24%312K | -18.93%304K | 1.95%626K | 2.38%1.51M | 0.53%379K | 5.31%377K | 1.35%375K | 1.66%614K | 6.67%1.47M | 8.65%377K |
| -Depreciation and amortization | -17.24%312K | -18.93%304K | 1.95%626K | 2.38%1.51M | 0.53%379K | 5.31%377K | 1.35%375K | 1.66%614K | 6.67%1.47M | 8.65%377K |
| Operating profit | 15.13%-1.17M | -361.95%-1.04M | -209.75%-731K | -469.75%-1.96M | -119.76%-113K | -1,138.35%-1.38M | -213.00%-226K | 37.23%-236K | 173.57%529K | -48.70%572K |
| Net non-operating interest income (expenses) | 4.35%96K | 5.26%100K | 18.37%116K | 313.73%422K | 101.47%137K | 64.29%92K | 1,457.14%95K | 753.33%98K | 288.89%102K | 585.71%68K |
| Non-operating interest income | -1.77%111K | 0.86%117K | 10.74%134K | 95.00%507K | 70.65%157K | 39.51%113K | 182.93%116K | 163.04%121K | 42.86%260K | 91.67%92K |
| Non-operating interest expense | -28.57%15K | -19.05%17K | -21.74%18K | -46.20%85K | -16.67%20K | -16.00%21K | -56.25%21K | -62.30%23K | -33.05%158K | -61.29%24K |
| Other net income (expenses) | 471.43%40K | 131.58%18K | -135.48%-11K | 101.76%4K | -71.25%23K | 16.67%7K | 75.22%-57K | 137.35%31K | 3.81%-227K | 229.03%80K |
| Gain on sale of security | 1,900.00%36K | 124.24%16K | -108.70%-2K | 92.94%-12K | -69.16%33K | -128.57%-2K | 69.01%-66K | 132.39%23K | 30.33%-170K | 252.86%107K |
| Income before tax | 19.19%-1.04M | -392.55%-926K | -485.05%-626K | -478.71%-1.53M | -93.47%47K | -757.44%-1.28M | -408.11%-188K | 77.43%-107K | 140.04%404K | -30.70%720K |
| Income tax | 0 | 0 | 0 | 199.56%456K | 143.01%197K | 0 | 93K | 166K | -577.08%-458K | -458K |
| Earnings from equity interest net of tax | ||||||||||
| Net income | 19.19%-1.04M | -229.54%-926K | -129.30%-626K | -330.39%-1.99M | -112.73%-150K | -757.44%-1.28M | -659.46%-281K | 42.41%-273K | 178.01%862K | 24.92%1.18M |
| Net income continuous operations | 19.19%-1.04M | -229.54%-926K | -129.30%-626K | -330.39%-1.99M | -112.73%-150K | -757.44%-1.28M | -659.46%-281K | 42.41%-273K | 178.01%862K | 24.92%1.18M |
| Noncontrolling interests | ||||||||||
| Net income attributable to the company | 19.19%-1.04M | -229.54%-926K | -129.30%-626K | -330.39%-1.99M | -112.73%-150K | -757.44%-1.28M | -659.46%-281K | 42.41%-273K | 178.01%862K | 24.92%1.18M |
| Preferred stock dividends | ||||||||||
| Other under preferred stock dividend | ||||||||||
| Net income attributable to common stockholders | 19.19%-1.04M | -229.54%-926K | -129.30%-626K | -330.39%-1.99M | -112.73%-150K | -757.44%-1.28M | -659.46%-281K | 42.41%-273K | 178.01%862K | 24.92%1.18M |
| Diluted earnings per share | 16.67%-0.05 | -400.00%-0.05 | -200.00%-0.03 | -350.00%-0.1 | -116.67%-0.01 | -700.00%-0.06 | -462.43%-0.01 | 50.00%-0.01 | 180.00%0.04 | 20.00%0.06 |
| Basic earnings per share | 16.67%-0.05 | -400.00%-0.05 | -200.00%-0.03 | -350.00%-0.1 | -116.67%-0.01 | -700.00%-0.06 | -462.43%-0.01 | 50.00%-0.01 | 180.00%0.04 | 20.00%0.06 |
| Dividend per share | ||||||||||
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.